Canada produces world-leading science, engineering, and AI research. So why does so much of that research still commercialize outside of Canada?
In this episode of TechSurge, host Nic Brathwaite puts that question to four leaders at two of Canada's top research universities: Mary Wells (Dean of Engineering) and Chris Houser (Dean of Science) at the University of Waterloo, and Heather Sheardown (Dean of Engineering) and Gianni Parise (VP Research) at McMaster.
At Waterloo, Mary Wells traces how the university's origin produced one of the world's most influential co-op programs and a creator-owned IP policy that lets inventors keep their ideas, making the school a talent engine for global tech. The group digs into Canada's AI paradox, foundational research and talent but far less of the economic value, and what quantum, robotics, and advanced manufacturing show about getting research to market.
McMaster runs a different model, built on health sciences, nuclear research, and problem-based learning. Heather Sheardown explains the McMaster Method and why it matters in an AI-shaped future. Gianni Parise argues for commercialization as a core university function, with work spanning AI-assisted drug discovery, inhaled vaccines, critical-mineral-free motors, and a campus nuclear reactor that supplies much of the world's iodine-125 for prostate cancer treatment. They also unpack Fusion Pharmaceuticals, the McMaster spin-out acquired by AstraZeneca, and what it reveals about university commercialization.
Together, these conversations ask what universities must become in an era defined by AI, deep tech, national competitiveness, and the urgent need to move ideas from the lab into the world.
Sign up for our newsletter at techsurgepodcast.com for updates on upcoming TechSurge Live Summits and future episodes.
0:00 Highlights 0:56 Welcome 2:39 Waterloo’s origin story 4:51 Creator-owned IP and the Waterloo model 7:42 The Co-op Flywheel 8:56 Canada’s AI paradox: world-class research, slower domestic value capture 10:21 AI, Regulation, Trust, and Canadian Competitiveness 17:09 Rethinking the PhD for Commercialisation 21:43 Inside Waterloo’s labs 30:14 What Waterloo wants to be in ten years: builders of the country 32:39 Meet McMaster: health sciences, nuclear capability, and research intensity 34:12 The McMaster Method 35:11 Research, Health, and Commercialisation 40:45 McMaster Labs: Heat, Motors and Health Innovation 47:13 Bioinnovation, Nuclear Research and Fusion Pharmaceuticals 58:43 The university of 2035: less lecture, deeper societal impact
Podden och tillhörande omslagsbild på den här sidan tillhör
Celesta Capital | Deep Tech Venture Capital Firm. Innehållet i podden är skapat av Celesta Capital | Deep Tech Venture Capital Firm och inte av,
eller tillsammans med, Poddtoppen.